International Research Journal of Education and Technology
Peer Reviewed Journal
ISSN 2581-7795

Advancements in Multi-Drug Therapy for Tuberculosis Prevention and Management

Kusuma V.Research Scholar, Malwanchal University. Indore

Dr Payal Sharma, Research Supervisor, Malwanchal University. Indore

Introduction

Tuberculosis (TB) remains a significant global health concern, causing millions of deaths each year despite being a preventable and treatable disease. One of the most effective strategies in combating TB is the use of multi-drug therapy (MDT). MDT involves the simultaneous use of several antibiotics to target the TB bacteria, which helps prevent the development of drug resistance and improves treatment outcomes. In this article, we'll explore the importance of MDT in both the prevention and management of tuberculosis among patients.

Understanding Tuberculosis

Tuberculosis is an infectious disease caused by the bacterium Mycobacterium tuberculosis. It primarily affects the lungs but can also affect other parts of the body, such as the kidneys, spine, and brain. TB spreads through the air when an infected individual coughs or sneezes, making it highly contagious.

The symptoms of TB include persistent cough, fever, night sweats, and weight loss. If left untreated, TB can be fatal. Treatment typically involves a combination of antibiotics taken over several months to ensure that all bacteria are eradicated from the body.

Challenges in Tuberculosis Treatment

One of the biggest challenges in TB treatment is the development of drug-resistant strains of the bacteria. This occurs when TB bacteria mutate and become resistant to one or more of the antibiotics used to treat the infection. Drug-resistant TB is much harder to treat and requires longer, more complex treatment regimens, often with more potent and expensive drugs.

Another challenge is ensuring patient adherence to treatment. TB treatment requires taking multiple antibiotics for an extended period, which can be difficult for patients, particularly in resource-limited settings where access to healthcare services may be limited.

The Role of Multi-Drug Therapy

Multi-drug therapy (MDT) has revolutionized the treatment of tuberculosis by addressing these challenges. MDT involves the simultaneous use of several antibiotics that are effective against TB bacteria. The most commonly used drugs in MDT are isoniazid, rifampicin, pyrazinamide, and ethambutol.

The use of multiple drugs targets different aspects of the TB bacteria's biology, making it harder for the bacteria to develop resistance. This approach significantly reduces the risk of drug-resistant TB developing during treatment.

Prevention of Tuberculosis with MDT

In addition to treating active TB infection, MDT is also used in the prevention of tuberculosis. Individuals who have been exposed to TB but have not yet developed active disease may be prescribed a course of antibiotics to prevent the infection from taking hold. This is known as preventive therapy.

Preventive therapy is particularly important for individuals who are at high risk of developing TB, such as those living with HIV or other conditions that weaken the immune system. By treating latent TB infection before it progresses to active disease, MDT helps reduce the overall burden of TB in communities.

Management of Tuberculosis with MDT

For individuals diagnosed with active TB disease, MDT is the standard of care for treatment. The World Health Organization (WHO) recommends a six-month course of MDT for most cases of drug-sensitive TB. This involves a combination of isoniazid, rifampicin, pyrazinamide, and ethambutol taken daily for the first two months, followed by isoniazid and rifampicin for an additional four months.

For drug-resistant TB, treatment is much more complex and may involve second-line antibiotics that are less effective and more toxic than first-line drugs. However, even in these cases, MDT principles still apply, with a combination of drugs used to target the bacteria from multiple angles.

Advancements in MDT

Research into tuberculosis treatment continues to advance, leading to new and improved drugs for MDT. One notable advancement is the development of shorter, more tolerable treatment regimens that reduce the duration and side effects of therapy while maintaining effectiveness.

Another area of research is the development of new drugs to treat drug-resistant TB. Bedaquiline and delamanid are two examples of newer drugs that have shown promise in treating multidrug-resistant TB when used in combination with other antibiotics.

Challenges and Future Directions

Despite the effectiveness of MDT, challenges remain in the fight against tuberculosis. Access to diagnosis and treatment remains a significant barrier in many parts of the world, particularly in low- and middle-income countries where TB burden is highest.

Drug resistance also continues to be a concern, with the emergence of extensively drug-resistant TB (XDR-TB) posing a particularly serious threat to global health. Addressing these challenges will require continued investment in research and development of new drugs, as well as efforts to strengthen healthcare systems and improve access to care for all individuals affected by TB.

Conclusion

Multi-drug therapy plays a critical role in both the prevention and management of tuberculosis among patients. By using a combination of antibiotics to target the TB bacteria from multiple angles, MDT helps prevent the development of drug resistance and improves treatment outcomes. As research into tuberculosis treatment continues to advance, it is hoped that new drugs and treatment regimens will further improve the effectiveness and accessibility of MDT, ultimately helping to reduce the global burden of TB.

Reference

1) World Health Organisation. Global tuberculosis report 2020. Geneva, World Health Organisation, 2020.

2) World Health Organisation. WHO consolidated guidelines on tuberculosis: tuberculosis preventive treatment: Module 1: prevention. Geneva, World Health Organisation, 2020.

3) Selwyn PA, Hartel D, Lewis VA, et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med 1989; 320: 545–550. doi:10.1056/NEJM198903023200901
4) Uplekar M, Weil D, Lonnroth K, et al. WHO's new end TB strategy. Lancet 2015; 385: 1799–1801. doi:10.1016/S0140-6736(15)60570-0
5) Centers for Disease Control and Prevention. World Tuberculosis Day. 2021. www.cdc.gov/tb/features/wtbd/2021WTBD_Feature.html Date last updated: 4 March 2021.

6) World Health Organisation. WHO announces updated definitions of extensively drug-resistant tuberculosis. 2021. https://www.who.int/news/item/27-01-2021-who-announces-updated-definitions-of-extensively-drug-resistant-tuberculosis Date last updated: 27 January 2021.
7) Asmar S, Drancourt M. Rapid culture-based diagnosis of pulmonary tuberculosis in developed and developing countries. Front Microbiol 2015; 6: 1184. doi:10.3389/fmicb.2015.01184
8) World Health Organisation. Policy framework for implementing new tuberculosis diagnostics. Geneva, World Health Organisation, 2010.
9) Horne DJ, Royce SE, Gooze L, et al. Sputum monitoring during tuberculosis treatment for predicting outcome: systematic review and meta-analysis. Lancet Infect Dis 2010; 10: 387–394. doi:10.1016/S1473-3099(10)70071-2

10) Sulis G, Centis R, Sotgiu G, et al. Recent developments in the diagnosis and management of tuberculosis. NPJ Prim Care Respir Med 2016; 26: 16078. doi:10.1038/npjpcrm.2016.78
11) Bhalla M, Sidiq Z, Sharma PP, et al. Performance of light-emitting diode fluorescence microscope for diagnosis of tuberculosis. Int J Mycobacteriol 2013; 2: 174–178. doi:10.1016/j.ijmyco.2013.05.001

12) Deng Y, Duan Y-F, Ga S-P, et al. Comparison of LAMP, GeneXpert, mycobacterial culture, smear microscopy, TSPOT.TB, TBAg/PHA ratio for diagnosis of pulmonary tuberculosis. Curr Med Sci 2021; 41: 1023–1028. doi:10.1007/s11596-021-2404-4
13) Singhal R, Myneedu VP. Microscopy as a diagnostic tool in pulmonary tuberculosis. Int J Mycobacteriol 2015; 4: 1–6. doi:10.1016/j.ijmyco.2014.12.006
14) Gilpin C, Kim SJ, Lumb R, et al. Critical appraisal of current recommendations and practices for tuberculosis sputum smear microscopy. Int J Tuberc Lung Dis 2007; 11: 946–952.
15) Lawn SD, Mwaba P, Bates M, et al. Advances in tuberculosis diagnostics: the Xpert MTB/RIF assay and future prospects for a point-of-care test. Lancet Infect Dis 2013; 13: 349–361. doi:10.1016/S1473-3099(13)70008-2
16) Steingart KR, Schiller I, Horne DJ, et al. Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev 2014; 1: CD009593. Doi:10.1002/14651858.CD009593.pub3
17) Dorman SE, Schumacher SG, Alland D, et al. Xpert MTB/RIF Ultra for detection of Mycobacterium tuberculosis and rifampicin resistance: a prospective multicentre diagnostic accuracy study. Lancet Infect Dis 2018; 18: 76–84. doi:10.1016/S1473-3099(17)30691-6

18) Arend SM, van Soolingen D. Performance of Xpert MTB/RIF Ultra: a matter of dead or alive. Lancet Infect Dis 2018; 18: 8–10. doi:10.1016/S1473-3099(17)30695-3